-
PloS One 2021Although Idiopathic Parkinson's disease (IPD) develops in considerable patients with drug-induced Parkinsonism (DIP), the association hasn't been well defined. We aimed...
BACKGROUND
Although Idiopathic Parkinson's disease (IPD) develops in considerable patients with drug-induced Parkinsonism (DIP), the association hasn't been well defined. We aimed to evaluate the underlying association and risk factors of DIP and IPD.
METHODS
A retrospective cohort study using National Health Insurance Claims data in 2011-2016 was conducted. New-onset DIP patients in 2012 were selected and matched with active controls having diabetes mellitus at a 1:4 ratio by age, sex, and Charlson's Comorbidity Index score. Comorbidity, causative drugs, and prescription days were evaluated as covariates.
RESULTS
A total of 441 DIP were selected. During the 4-year follow up, 14 IPD events in the DM group but 62 events in the DIP group were observed (adjusted hazard ratio, HR: 18.88, 95% CI, 9.09-39.22, adjusting for comorbidities and causative drugs). IPD diagnosis in DIP was observed high in males compared to females (15.58/13.24%). The event was the most within the 1st year follow-up, mean days 453 (SD 413.36). Subgroup analysis in DIP showed calcium channel blocker (verapamil, diltiazem, and flunarizine) was significantly associated with increased IPD risk (HR: 2.24, 95% CI, 1.27-3.93).
CONCLUSION
Increased IPD in DIP patients might not be from the causal toxicity of antidopaminergic effects but from a trigger by the causative drugs on the DIP patients who already had subclinical IPD pathology. DIP can serve as a strong proxy for IPD incidence. Subjects who develop DIP should be monitored carefully for potential IPD incidence.
Topics: Aged; Aged, 80 and over; Calcium Channel Blockers; Cohort Studies; Comorbidity; Diabetes Mellitus; Female; Humans; Incidence; Male; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary; Parkinsonian Disorders; Proportional Hazards Models; Republic of Korea; Retrospective Studies; Risk Factors
PubMed: 33647030
DOI: 10.1371/journal.pone.0247354 -
A.M.A. Archives of Internal Medicine Apr 1952
Topics: Heat Stroke; Humans; Parkinson Disease; Parkinsonian Disorders
PubMed: 14902165
DOI: 10.1001/archinte.1952.00240040041005 -
Neurology Jun 1961
Topics: Humans; Parkinson Disease; Parkinsonian Disorders
PubMed: 13707839
DOI: 10.1212/wnl.11.6.538 -
British Medical Journal Sep 1958
Topics: Humans; Parkinson Disease; Parkinsonian Disorders
PubMed: 13572886
DOI: No ID Found -
British Medical Journal Apr 1957
Topics: Parkinson Disease; Parkinsonian Disorders
PubMed: 13413243
DOI: No ID Found -
Current Aging Science Feb 2022Parkinsonism is a neurodegenerative disorder that affects elderly people worldwide.
BACKGROUND
Parkinsonism is a neurodegenerative disorder that affects elderly people worldwide.
METHODS
Curcumin, adenosine AR antagonist (ZM241385) and Sinemet (L-dopa) were evaluated against Parkinson's disease (PD) induced by rotenone in rats, and the findings were compared to our previous study on mice model.
RESULTS
Rats injected with rotenone showed severe alterations in adenosine A receptor gene expression, oxidative stress markers, inflammatory mediator, energetic indices, apoptotic marker and DNA fragmentation levels as compared to the control group. Treatments with curcumin, ZM241385, and Sinemet restored all the selected parameters. The brain histopathological features of cerebellum regions confirmed our results. By comparing our results with the previous results on mice, we noticed that mice respond to rotenone toxicity and treatments more than rats with regards to behavioral observation, AR gene expression, neurotransmitter levels, inflammatory mediator and apoptotic markers, while rats showed higher response to treatments regarding oxidative stress and energetic indices.
CONCLUSION
Curcumin succeeded in attenuating the severe effects of Parkinson's disease in the rat model and can be considered as a potential dietary supplement. Adenosine AR antagonist has almost the same pattern of improvement as Sinemet and may be considered as a promising therapy against PD. To compare the role of animal species in response to PD symptoms and treatments, our previous report on mice explored the response of mice to rotenone toxicity in comparison with rats, where rats have shown a higher response to treatments. Therefore, no animal model can perfectly recapitulate all the pathologies of PD.
Topics: Adenosine; Aged; Animals; Curcumin; Disease Models, Animal; Dopamine Agonists; Humans; Inflammation Mediators; Mice; Neuroprotective Agents; Parkinson Disease; Parkinsonian Disorders; Rats; Receptor, Adenosine A2A; Rotenone
PubMed: 34042043
DOI: 10.2174/1874609814666210526115740 -
Journal of Parkinson's Disease 2023Little is known about the burden of parkinsonism and Parkinson's disease (PD) in Latin America. Better understanding of health service use and clinical outcomes in PD is...
BACKGROUND
Little is known about the burden of parkinsonism and Parkinson's disease (PD) in Latin America. Better understanding of health service use and clinical outcomes in PD is needed to improve its prognosis.
OBJECTIVE
The aim of the study was to estimate the burden of parkinsonism and PD in six Latin American countries.
METHODS
12,865 participants aged 65 years and older from the 10/66 population-based cohort study were analysed. Baseline assessments were conducted in 2003-2007 and followed-up 4 years later. Parkinsonism and PD were defined using current clinical criteria or self-reported diagnosis. Logistic regression models assessed the association between parkinsonism/PD with baseline health service use (community-based care or hospitalisation in the last 3 months) and Cox proportional hazards regression models with incident dependency (subjective assessment by interviewer based on informant interview) and mortality. Separate analyses for each country were combined via fixed effect meta-analysis.
RESULTS
At baseline, the prevalence of parkinsonism and PD was 7.9% (nā=ā934) and 2.6% (nā=ā317), respectively. Only parkinsonism was associated with hospital admission at baseline (OR 1.89, 95% CI 1.30-2.74). Among 7,296 participants without dependency at baseline, parkinsonism (HR 2.34, 95% CI 1.81-3.03) and PD (2.10, 1.37-3.24) were associated with incident dependency. Among 10,315 participants with vital status, parkinsonism (1.73, 1.50-1.99) and PD (1.38, 1.07-1.78) were associated with mortality. The Higgins I2 tests showed low to moderate levels of heterogeneity across countries.
CONCLUSIONS
Our findings show that older people with parkinsonism or PD living in Latin America have higher risks of developing dependency and mortality but may have limited access to health services.
Topics: Aged; Humans; Cohort Studies; Latin America; Parkinson Disease; Parkinsonian Disorders; Patient Acceptance of Health Care
PubMed: 37742660
DOI: 10.3233/JPD-230114 -
Annals of Neurology Apr 2006
Review
Topics: Aged; Humans; Male; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Parkinsonian Disorders
PubMed: 16566021
DOI: 10.1002/ana.20834 -
Journal of the Neurological Sciences Sep 2013Differentiating Parkinson's disease (PD) from other types of neurodegenerative atypical parkinsonism (AP) can be challenging, especially in early disease stages. Routine... (Review)
Review
Differentiating Parkinson's disease (PD) from other types of neurodegenerative atypical parkinsonism (AP) can be challenging, especially in early disease stages. Routine brain magnetic resonance imaging (MRI) can show atrophy or signal changes in several parts of the brain with fairly high specificity for particular forms of AP, but the overall diagnostic value of routine brain MRI is limited. In recent years, various advanced MRI sequences have become available, including diffusion weighted imaging (DWI) and diffusion tensor imaging (DTI). Here, we review available literature on the value of diffusion MRI for identifying and quantifying different patterns of neurodegeneration in PD and AP, in relation to what is known of underlying histopathologic changes and clinical presentation of these diseases. Next, we evaluate the value of diffusion MRI to differentiate between PD and AP and the potential value of serial diffusion MRI to monitor disease progression. We conclude that diffusion MRI may quantify patterns of neurodegeneration which could be of additional value in clinical use. Future prospective clinical cohort studies are warranted to assess the added diagnostic value of diffusion MRI.
Topics: Brain; Diffusion Magnetic Resonance Imaging; Humans; Parkinson Disease; Parkinsonian Disorders
PubMed: 23866820
DOI: 10.1016/j.jns.2013.06.032 -
Parkinsonism & Related Disorders Jun 2021
Topics: COVID-19; Communicable Disease Control; Deep Brain Stimulation; Humans; Male; Parkinson Disease; Parkinsonian Disorders; SARS-CoV-2
PubMed: 33940565
DOI: 10.1016/j.parkreldis.2021.04.010